Note: Ingredients listed on restricted chemical lists
EC/CAS
231-131-3/7440-22-4
Name of the chemical
Silver
Concentration
<=100
General Information
Version
4
Revision date
2024-03-24
Product name
Silver nanopowder
CAS No.
7440-22-4
Emergency telephone
001-800-227-6701, +32 14 57 52 11, 001-201-796-7100, +32 14 57 52 99, 001-800-424-9300, 001-703-527-3887, +41-44 251 51 51, +41-43 508 20 11
Icons in SDS
Company Information
company name
Thermo Fisher (Kandel) GmbH
e-mail address of the competent person responsible for the Safety Data Sheet
begel.sdsdesk@thermofisher.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H360D, H400, H410
Hazard statements
Code
Statements
H360D
May damage the unborn child
Section 2
SECTION 2: Hazards identification
CLP Classification - Regulation (EC) No 1272/2008 Classification of the substance or mixture
Physical hazards
Based on available data, the classification criteria are not met
Health hazards
Reproductive Toxicity Category 1A (H360D)
Environmental hazards
Acute aquatic toxicity Category 1 (H400) Chronic aquatic toxicity Category 1 (H410) Full text of Hazard Statements: see section 16
Signal word
Danger
Hazard statements
H360D - May damage the unborn child H410 - Very toxic to aquatic life with long lasting effects
Precautionary statements
P201 - Obtain special instructions before use P280 - Wear protective gloves/protective clothing/eye protection/face protection P308 + P313 - IF exposed or concerned: Get medical advice/attention Additional EU labelling Restricted to professional users
2.3 Other hazards
No information available This product does not contain any known or suspected endocrine disruptors
2.1 Classification of the substance or mixture
CLP Classification - Regulation (EC) No 1272/2008 Physical hazards Based on available data, the classification criteria are not met Health hazards Reproductive Toxicity Category 1A (H360D) Environmental hazards Acute aquatic toxicity Category 1 (H400) Chronic aquatic toxicity Category 1 (H410) Full text of Hazard Statements: see section 16
